STOCK TITAN
  1. Home
  2. News
  3. AKTX

Akari Therapeutics Plc - AKTX STOCK NEWS

IMPACT
SENTIMENT
AKTX : Nasdaq
Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors
management
IMPACT
SENTIMENT
AKTX : Nasdaq
Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference
clinical trial
IMPACT
SENTIMENT
AKTX : Nasdaq
Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference
conferences clinical trial
IMPACT
SENTIMENT
AKTX : Nasdaq
Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
earnings
IMPACT
SENTIMENT
AKTX : Nasdaq
Akari Therapeutics to Present at Emerging Growth Conference
conferences acquisition
IMPACT
SENTIMENT
AKTX : Nasdaq
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit
IMPACT
SENTIMENT
AKTX : Nasdaq
Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs
conferences
IMPACT
SENTIMENT
AKTX : Nasdaq
Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
IMPACT
SENTIMENT
AKTX : Nasdaq
Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials
clinical trial
IMPACT
SENTIMENT
AKTX : Nasdaq
Akari Therapeutics, Plc Announces ADS Ratio Change
Stock AKTX logo
Akari Therapeutics Plc

Nasdaq:AKTX

AKTX Rankings

#6885 Ranked by Market Cap
#4941 Ranked by Stock Gains
N/A Ranked by Dividends

AKTX Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About AKTX

akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.